Mostrar el registro sencillo del ítem

dc.contributor.authorIngle, Suzanne M
dc.contributor.authorMay, Margaret T
dc.contributor.authorGill, M John
dc.contributor.authorMugavero, Michael J
dc.contributor.authorLewden, Charlotte
dc.contributor.authorAbgrall, Sophie
dc.contributor.authorFätkenheuer, Gerd
dc.contributor.authorReiss, Peter
dc.contributor.authorSaag, Michael S
dc.contributor.authorManzardo, Christian
dc.contributor.authorGrabar, Sophie
dc.contributor.authorBruyand, Mathias
dc.contributor.authorMoore, David
dc.contributor.authorMocroft, Amanda
dc.contributor.authorSterling, Timothy R
dc.contributor.authord'Arminio Monforte, Antonella
dc.contributor.authorHernando Sebastian, Victoria 
dc.contributor.authorTeira, Ramon
dc.contributor.authorGuest, Jodie
dc.contributor.authorCavassini, Matthias
dc.contributor.authorCrane, Heidi M
dc.contributor.authorSterne, Jonathan A C
dc.date.accessioned2019-02-04T10:58:07Z
dc.date.available2019-02-04T10:58:07Z
dc.date.issued2014-07-15
dc.identifier.citationClin Infect Dis. 2014; 59(2):287-97es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7083
dc.description.abstractBACKGROUND: Patterns of cause-specific mortality in individuals infected with human immunodeficiency virus type 1 (HIV-1) are changing dramatically in the era of antiretroviral therapy (ART). METHODS: Sixteen cohorts from Europe and North America contributed data on adult patients followed from the start of ART. Procedures for coding causes of death were standardized. Estimated hazard ratios (HRs) were adjusted for transmission risk group, sex, age, year of ART initiation, baseline CD4 count, viral load, and AIDS status, before and after the first year of ART. RESULTS: A total of 4237 of 65 121 (6.5%) patients died (median, 4.5 years follow-up). Rates of AIDS death decreased substantially with time since starting ART, but mortality from non-AIDS malignancy increased (rate ratio, 1.04 per year; 95% confidence interval [CI], 1.0-1.1). Higher mortality in men than women during the first year of ART was mostly due to non-AIDS malignancy and liver-related deaths. Associations with age were strongest for cardiovascular disease, heart/vascular, and malignancy deaths. Patients with presumed transmission through injection drug use had higher rates of all causes of death, particularly for liver-related causes (HRs compared with men who have sex with men: 18.1 [95% CI, 6.2-52.7] during the first year of ART and 9.1 [95% CI, 5.8-14.2] thereafter). There was a persistent role of CD4 count at baseline and at 12 months in predicting AIDS, non-AIDS infection, and non-AIDS malignancy deaths. Lack of viral suppression on ART was associated with AIDS, non-AIDS infection, and other causes of death. CONCLUSIONS: Better understanding of patterns of and risk factors for cause-specific mortality in the ART era can aid in development of appropriate care for HIV-infected individuals and inform guidelines for risk factor management.es_ES
dc.description.sponsorshipinfoThis work was supported by the UK Medical Research Council and the Department for International Development (grants G0700820 and MR/J002380/1). J. S. was supported by National Institute for Health Research (NIHR) Senior Investigator Award NF-SI-0611-10168. Sources of funding of individual cohorts include the Agence Nationale de Recherche sur le SIDA et les hépatites virales; the Institut National de la Santé et de la Recherche Médicale; the French, Italian and Spanish Ministries of Health; the Swiss National Science Foundation (grant 33CS30_134277); the Ministry of Science and Innovation and the “Spanish Network for AIDS Research (RIS; ISCIII-RETIC RD06/006); the Stichting HIV Monitoring; the European Commission (EuroCoord grant 260694); the British Columbia and Alberta governments; the National Institutes of Health (NIH) [UW Center for AIDS Research (CFAR)] (NIH grant P30AI027757); University of Alabama at Birmingham (UAB) CFAR (NIH grant P30-AI027767); the Vanderbilt-Meharry CFAR (NIH grant P30AI54999); the National Institute on Alcohol Abuse and Alcoholism (U10-AA13566, U24-AA020794); the US Department of Veterans Affairs; the Michael Smith Foundation for Health Research; the Canadian Institutes of Health Research; the VHA Office of Research and Development; and unrestricted grants from Abbott, Gilead, Tibotec-Upjohn, ViiV Healthcare, MSD, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche, and Boehringer-Ingelheim.es_ES
dc.language.isoenges_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/*
dc.subjectHIVes_ES
dc.subjectAntiretroviral therapyes_ES
dc.subjectCause-specific mortalityes_ES
dc.subject.meshAdolescent es_ES
dc.subject.meshAdult es_ES
dc.subject.meshAged es_ES
dc.subject.meshAntiretroviral Therapy, Highly Active es_ES
dc.subject.meshCause of Death es_ES
dc.subject.meshCohort Studies es_ES
dc.subject.meshEurope es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHIV Infections es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshNorth America es_ES
dc.subject.meshRisk Factors es_ES
dc.subject.meshYoung Adult es_ES
dc.titleImpact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patientses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-3.0 Internacional*
dc.identifier.pubmedID24771333es_ES
dc.format.volume59es_ES
dc.format.number2es_ES
dc.format.page287-97es_ES
dc.identifier.doi10.1093/cid/ciu261es_ES
dc.contributor.funderMedical Research Council (Reino Unido) 
dc.contributor.funderNational Institutes of Health (Estados Unidos) 
dc.contributor.funderAgence Nationale de Recherches sur le sida et les hépatites virales (Francia) 
dc.contributor.funderInstitut National de la Santé et de la Recherche Médicale (Francia) 
dc.contributor.funderMinisterio de Sanidad, Servicios Sociales e Igualdad (España) 
dc.contributor.funderMinistère de la Santé (Francia) 
dc.contributor.funderMinistero della Salute (Italia) 
dc.contributor.funderSwiss National Science Foundation 
dc.contributor.funderMinisterio de Ciencia e Innovación (España) 
dc.contributor.funderUnión Europea. Comisión Europea 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1537-6591es_ES
dc.identifier.journalClinical infectious diseases : an official publication of the Infectious Diseases Society of Americaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/ISCIII-RETIC RD06/006es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/260694es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-3.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-3.0 Internacional